A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

BACKGROUND: Microsatellite‐stable (MSS) colorectal cancer (CRC) tends to be poorly immunogenic, with limited treatment options. In MSS CRC xenograft models, trifluridine/tipiracil (FTD/TPI) plus programed death 1 inhibitors resulted in synergistic antitumor activity and increased tumor immunogenicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Manish R., Falchook, Gerald S., Hamada, Kensuke, Makris, Lukas, Bendell, Johanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926002/
https://www.ncbi.nlm.nih.gov/pubmed/33544407
http://dx.doi.org/10.1002/cam4.3630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926002/
https://www.ncbi.nlm.nih.gov/pubmed/33544407
http://dx.doi.org/10.1002/cam4.3630

Ejemplares similares